Skip to main content

Advertisement

SpringerLink
Log in

A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series

  • Original Article
  • Published:
Irish Journal of Medical Science Aims and scope Submit manuscript

Abstract

Background

The combination chemotherapy regimen of streptozocin and 5-fluorouracil (FU/STZ) has been used for the treatment of metastatic neuroendocrine tumours.

Aim

The aim of this study was to analyse the use of this regimen in a tertiary oncology referral centre over a 10-year period.

Method

We retrospectively analysed nine cases from February 2000 to May 2010. Patient demographics, chemotherapy schedule, toxicities, progression-free and overall survival were tabulated for each patient.

Result

The median progression-free survival was 17 months (range 3–48+ months), and overall survival 31 months (range 12–53+ months) with no toxicity related deaths.

Conclusion

FU/STZ was a well-tolerated regimen that produced significant benefit in the setting of metastatic and progressive disease. Our case series demonstrated comparable progression-free survival and overall survival in relation to randomized controlled studies and previous case series.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Arnold R, Rinke A, Schmidt C, Hofbauer L (2005) Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol 19:649–665

    Article  PubMed  CAS  Google Scholar 

  2. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (2010) The pathologic classification of neuroendocrine tumors. Pancreas 39:707–712

    Article  PubMed  Google Scholar 

  3. Öberg K (2010) Pancreatic endocrine tumors. Semin Oncol 37:561–594

    Article  Google Scholar 

  4. Basu B, Sirhoni B, Corrie P (2008) Systemic therapy for neuroendocrine tumours of gastroenteropathic origin. Endocr Relat Cancer 17:75–90

    Article  Google Scholar 

  5. Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79:108–118

    PubMed  CAS  Google Scholar 

  6. Sun W, Lipsitz S, Catalano P, Maillaird JA, Haller DG (2003) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumours: ECOG Group Study E1281. J Clin Oncol 23:4897–4904

    Article  Google Scholar 

  7. Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194

    Article  PubMed  CAS  Google Scholar 

  8. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1998) Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523

    Article  Google Scholar 

  9. Moertel CG, Johnson CM, McKusick MA et al (1994) The management of patients with advanced carcinoid tumours and islet cell carcinomas. Ann Intern Med 120:302–309

    PubMed  CAS  Google Scholar 

  10. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C (2003) Localisaton of vascular endothelial growth factor and its receptors in digestive endocrine tumours: correlation with microvessel density and clinicopatologic features. Hum Pathol 34:18–27

    Article  PubMed  CAS  Google Scholar 

  11. Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumours. N Engl J Med 364:501–513

    Article  PubMed  CAS  Google Scholar 

  12. Phan A, Yao J, Fogelman D. (2010) A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide in advanced low-grade neuroendocrine carcinoma J Clin Oncol 28 (absract)

  13. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C (2007) MC044 h, a phase II trial of sorafenib in patients with metastatic neuroendocine tumors: a phase II consortium study [abstract]. ASCO Annual Meeting Proc 25:4505a

    Google Scholar 

  14. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumours. N Engl J Med 364:514–523

    Article  PubMed  CAS  Google Scholar 

  15. O’Donnell PH, Ratatin MJ (2007) Evaluating the activity of temsirolimus in neuroendocrine cancer. Br J Cancer 177:177–179

    Article  Google Scholar 

  16. Castellano D (2011) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801)

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Trinity College Dublin, St. James’s Hospital, James’s Street, Dublin 2, Ireland

    J. Naidoo, D. O’Toole, M. J. Kennedy, J. V. Reynolds & K. O’Byrne

  2. Waterford Regional Hospital, Dunmore Road, Waterford, Ireland

    J. Naidoo & M. O’Connor

Authors
  1. J. Naidoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. O’Toole
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. J. Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. V. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. O’Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Naidoo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naidoo, J., O’Toole, D., Kennedy, M.J. et al. A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. Ir J Med Sci 181, 211–214 (2012). https://doi.org/10.1007/s11845-011-0780-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-011-0780-7

Keywords

Search

Navigation